New imaging agent could sharpen pancreatic cancer detection

NCT ID NCT05262855

Completed Diagnosis Sponsor: SOFIE Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a radioactive tracer called [68Ga]FAPI-46, used with a PET scan, to see if it can better detect pancreatic cancer cells. 63 adults with early-stage pancreatic cancer received the tracer before surgery. The goal was to see how well the scan matches the actual cancer found during surgery. If it works well, this could help doctors plan more precise surgeries.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [68Ga]FAPI-46 (a radioactive tracer for PET imaging)
What this could lead to: If successful, this imaging method could help doctors more accurately detect and stage pancreatic cancer, leading to better surgical decisions.
What could go wrong: This is a small, early-phase study (63 participants) and the tracer is only for imaging, not treatment. It may not improve outcomes or be widely available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FAP are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic familial adenomatous polyposis pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FAP PDAC - PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

BAMF Health

Grand Rapids, Michigan, 49503, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
NYU Langone Health

New York, New York, 10016, United States
University of California Los Angeles (UCLA) Health

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.